key: cord-0295435-sn0f4ijz authors: Shurrab, F. M.; Younes, N.; Al-Sadeq, D. W.; Qotba, H.; Abu-Raddad, L. J.; Nasrallah, G. title: Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantitation of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals date: 2022-01-05 journal: nan DOI: 10.1101/2022.01.04.22268717 sha: f9f3ebbdb3c5e0498ee59bf1e074b877422b7567 doc_id: 295435 cord_uid: sn0f4ijz Background: The vast majority of the commercially available LFIA is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based LIFA test was developed for quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim: To evaluate the performance of the fluorescence LIFA FinecareTM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113). Methods: Plasma from 150 RT-PCR confirmed-positive individuals and 100 pre-pandemic samples were tested by FinCareTm to access sensitivity and specificity. For qualitative and quantitative validation of the FinCarTm measurements, the BAU/mL results of FinCareTm were compared with results of two reference assays: the surrogate virus-neutralizing test (sVNT, GenScript, USA), and the VIDAS3 automated assay (BioMerieux, France). Results: FinecareTM showed 92% sensitivity and 100% specificity compared to PCR. Cohen's Kappa statistic denoted moderate and excellent agreement with sVNT and VIDAS3, ranging from 0.557 (95% CI: 0.32-0.78) to 0.731 (95% CI: 0.51-0.95), respectively. A strong correlation was observed between FinecareTM/sVNT (r=0.7, p<0.0001) and FinecareTM/VIDAS3 (r=0.8, p<0.0001). Conclusion: FinecareTM is a reliable assay and can be used as a surrogate to assess binding and neutralizing antibody response post-infection or vaccination, particularly in none or small laboratory settings. Soon after the emergence of the severe acute respiratory syndrome 2 (SARS-CoV-2) in December 2019 and its declaration as a pandemic by the World Health Organization (WHO), the need for accurate, sensitive, and rapid detection of SARS-CoV-2 for the control and prevention of the disease was urgent (Theel et al., 2020) . Several commercial COVID-19 test kits were developed in response to this urgent need to detect either nucleic acid or antibodies (Van Walle et al., 2021). Although RT-PCR is used as a gold standard test, it requires specialized conditions, expensive equipment, and qualified personnel for sampling and testing. These limitations pose a challenge in a pandemic setting which requires rapid and reliable tests that can be used to screen populations (Dortet et al., 2021) . Thus, serological testing, particularly point of care approaches, such as the lateral flow immunoassay (LFIA), provides a rapid, portable, and coast effective method complementary to the RT-PCR. Conventional LFIA used in clinical settings for diagnosing SARS-CoV-2 infection are done manually within 15 minutes, and the results are interrupted qualitatively by the naked eye. As a result, errors due to manual operation and inadequate visual sensitivity interpretation can occur. Recently, Wondfo Biotech developed Fluorescence-based LIFA to detect total anti-S- Test is a fluorescence immunoassay that is done semiautomatically along with a small portable device. The combination of fluorescence and LIFA provides higher sensitivity, quantitative detection of antibodies. In addition, the test is easily affordable and accessible in small clinical laboratories, research settings, or point of care testing, including post-infection or vaccination. To the best of our knowledge, there is only one paper in the literature evaluating the rapid fluorescence based LFIA immunoassays, which aimed to validate the performance of rapid . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268717 doi: medRxiv preprint SARS CoV 2 IgM and IgG test kits based on fluorescence immunochromatography (Kang et al., 2021) . This study aimed to evaluate the performance of a rapid semiautomated fluorescencebased LIFA. This assay is designated to provide qualitative and quantitative measurements of SARS CoV 2 anti-S-RBD total antibodies. One of the most advantages of this assay over the commercially available LIFA is that results are quantitative and converted to BAU/mL (instead of arbitrary ARU/mL) as recently recommended by the WHO. We evaluated the performance of FineCare TM 2019-nCOV Antibody test and its reader The sensitivity FineCare TM was determined using 150 sera from RT-PCR-confirmed individuals (7 ->21 days). Complete descriptions for these participants are summarized in Table S1 , and the methodology for PCR detection methodology is described in the following paper . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; The FDA-approved SARS-CoV-2 surrogate virus neutralization test Vitro diagnostic (IVD) assay and granted the Emergency Use Authorization (EUA) by FDA in early 2021. The assay principle is based on a two-step enzyme immunoassay combined with an enzyme-linked fluorescent assay (ELFA) detection technique. The test uses a solid phase receptacle (SPR) coated with SARS-CoV-2 S-RBD of the spike protein. The test was done according to the manufactures' instructions. In brief, the test was calibrated with standard (S1), a positive control (C1), and negative control (C2). Then 100µl of the sample was added to the test strip. The results are generated as relative fluorescence value (RFV), and automatically calculated by the instrument; according to the S1 standard and sample RFV, an index value (i) is . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268717 doi: medRxiv preprint obtained (where i = RFV sample /RFV S1 ). The test is interpreted as negative when i < 1.00 and positive when i ≥ 1.00 (Renard et al., 2021) . All readings were standardized to Binding Antibody Units per milliliters (BAU/mL) by applying the WHO International Standard (20.33 BAU/mL) for the VIDAS®3 SARS-COV-2 IgG. Using the RT-PCR as the reference test, sensitivity, specificity, overall percent agreement, and Cohen's Kappa coefficient were calculated to assess the Performance of Receiving operating characteristic (ROC) curve and Youden index were conducted to assess the assay threshold (cut-off indices) and identify optimized one and measure the area under the curve (AUC). The relation between AUC and diagnostic accuracy is direct. The larger the AUC, the more accurate a test can be considered in its overall performance. Statistically, an AUC of <0.5 suggests no discrimination, 0.7-0.8 is considered acceptable, 0.8-0.9 is considered excellent, and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268717 doi: medRxiv preprint >0.9 is considered outstanding. To determine the optimal threshold for optimal sensitivity and specificity for FineCare TM , the Youden's index (J) was calculated using the formula: J= max (sensitivity + specificity) -1, (Fluss et al., 2005 , Unal and medicine, 2017). All statistical analyses were performed using GraphPad Prism version 9.3.0. The overall diagnostic performance of FineCare TM analyzer compared to RT-PCR is summarized in Table1 The tests' concordance assessment is summarized in is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268717 doi: medRxiv preprint ROC curve analyses showed excellent Performance for FineCare TM with an AUC of 0.9627, and p<0.0001 (Figure 2 ). Based on the ROC curves and the calculated Youden's index, the optimized cut-off for detecting total antibodies against RBD was derived. The cut-off obtained was > 10.70, compared to the manufacturer's cut-off ≥ 20. Applying this new cut-off showed improved sensitivity, from 92% to 94.67%, while the specificity remained 100% (Table 1 ). Earlier studies reported that the severity of the case affects the humoral response in patients (Wu et al., 2021 , Zhao et al., 2020 . Previously, we reported that the sensitivity of the immunoassay was higher in symptomatic patients than in the asymptomatic patient group . We evaluated the degree of correlation between FineCare TM with sVNT and VIDAS®3. A strong correlation was obtained between FineCare TM and both assays (Figure1); however, Test. An AUC of 0.9-1.0 is considered excellent, 0.8-0.9 very good, 0.7-0.8 good, 0.6-0.7 sufficient, 0.5-0.6 bad, and less than 0.5 considered not useful. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268717 doi: medRxiv preprint VIDAS®3 showed a slightly higher correlation. This is because both VIDAS®3 and FineCare TM detection methods are based on enzyme-linked fluorescent and target antibodies against the S-RBD domain. This is particularly important; the FineCare TM rapid antibody test could detect neutralizing antibodies and serve as a surrogate for the advanced automated immunoassays in clinical settings to measure the humoral immune response after vaccination or infection and research context. ROC curve analysis was also performed to determine the optimal cut-off indices for FineCare TM (Figure 2 ). The new cut-off value showed improved sensitivity without affecting the specificity. However, the cut-off values could be adjusted depending on the clinical setting or research context. For instance, in high-prevalence settings, higher thresholds may be desirable for screening purposes, whereas lower cut-off may be helpful for diagnosis purposes (Ismail et al., 2021) . Our study had some limitations; most of our RT-PCR samples were collected from asymptomatic individuals (Table S1 ), which might have underestimated the assay's sensitivity. In addition, the control group did not include samples for other coronaviruses or influenza that might cross-react with SARS-CoV-2, which could have led to an overestimated specificity. In conclusion, our data showed that FineCare TM 2019-RBD antibody test demonstrated excellent performance in terms of sensitivity, specificity, and overall agreement with RT-PCR as a reference test. In addition, correlation with the FDA-approved sVNT from Genscript and the automated analyzer VIDAS®3 from bioMérieux, FineCare TM immunoassay showed an outstanding performance in detecting total antibodies in serum samples against SARS-CoV-2. Thus, this assay could be reliable for the quantitative detection of antibodies in the vaccinated population and recovered patients. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268717 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268717 doi: medRxiv preprint 2019-nCoV RBD Antibody Tes 2019-nCoV RBD Antibody Test; Available from: www.wondfo.com.cn Evaluation of antibody response in symptomatic and asymptomatic COVID-19 patients and diagnostic assessment of new IgM/IgG ELISA kits Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar Comparison of classification accuracy using Cohen's Weighted Kappa Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Evaluating 10 commercially available SARS-CoV-2 rapid serological tests by use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) method Estimation of the Youden Index and its associated cut-off point Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays Development, performance evaluation, and clinical application of a Rapid SARS CoV 2 IgM and IgG Test Kit based on automated fluorescence immunoassay Interrater reliability: the kappa statistic Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT) Estimating seroprevalence of herpes simplex virus type 1 among different Middle East and North African male populations residing in Qatar Abu-Raddad LJJJoCV. Performance of four diagnostic assays for detecting herpes simplex virus type 2 antibodies in the Middle East and North Africa Performance Characteristics of the Vidas SARS-CoV-2 IgM and Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes Statistics at square one: Bmj London Epidemiology of SARS-CoV2 in Qatar's primary care population aged 10 years and above A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction The role of antibody testing for SARS-CoV-2: is there one? Defining an optimal cut-point value in ROC analysis: an alternative approach Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies Diagnostic efficiency of three fully automated serology assays and their correlation with a novel surrogate virus neutralization test in symptomatic and asymptomatic SARS-COV-2 individuals Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease WHO international standard for SARS-CoV-2 antibodies to determine markers of protection Funding: This work was made possible by grant number UREP28-1733-057 from the Qatar